AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 3 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 8.4%.
Links
Filings
- All filings
- Annual reports (20-F)
- Quarterly reports (6-K)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $3,649 | +182350.0% | 8,091 | +115485.7% | 0.00% | – |
Q1 2023 | $2 | -50.0% | 7 | -12.5% | 0.00% | – |
Q4 2022 | $4 | -100.0% | 8 | -100.0% | 0.00% | – |
Q2 2022 | $39,000 | -74.0% | 76,806 | +17.7% | 0.00% | – |
Q1 2022 | $150,000 | -76.9% | 65,276 | -52.2% | 0.00% | – |
Q4 2021 | $649,000 | +50.6% | 136,636 | +152.0% | 0.00% | – |
Q3 2021 | $431,000 | +19.1% | 54,220 | +4.1% | 0.00% | – |
Q2 2021 | $362,000 | -8.6% | 52,077 | +4.2% | 0.00% | – |
Q1 2021 | $396,000 | +10.9% | 49,973 | +10.2% | 0.00% | – |
Q4 2020 | $357,000 | +35.2% | 45,360 | +21.7% | 0.00% | – |
Q3 2020 | $264,000 | -34.5% | 37,285 | -14.4% | 0.00% | – |
Q2 2020 | $403,000 | +96.6% | 43,569 | -1.1% | 0.00% | – |
Q1 2020 | $205,000 | -51.2% | 44,036 | -19.9% | 0.00% | – |
Q4 2019 | $420,000 | -6.9% | 55,003 | -6.2% | 0.00% | – |
Q3 2019 | $451,000 | +53.9% | 58,669 | +37.2% | 0.00% | – |
Q2 2019 | $293,000 | -13.6% | 42,760 | +1.6% | 0.00% | – |
Q1 2019 | $339,000 | +6.3% | 42,097 | -1.2% | 0.00% | – |
Q4 2018 | $319,000 | -37.3% | 42,626 | -19.8% | 0.00% | – |
Q3 2018 | $509,000 | -35.1% | 53,170 | -28.2% | 0.00% | – |
Q2 2018 | $784,000 | +221.3% | 74,015 | +201.3% | 0.00% | – |
Q1 2018 | $244,000 | +3385.7% | 24,565 | +1752.6% | 0.00% | – |
Q4 2017 | $7,000 | -30.0% | 1,326 | -32.1% | 0.00% | – |
Q3 2017 | $10,000 | 0.0% | 1,954 | -25.1% | 0.00% | – |
Q2 2017 | $10,000 | +42.9% | 2,608 | +164.2% | 0.00% | – |
Q1 2017 | $7,000 | +133.3% | 987 | +23.4% | 0.00% | – |
Q4 2016 | $3,000 | -97.3% | 800 | -95.4% | 0.00% | – |
Q3 2016 | $112,000 | +220.0% | 17,371 | +141.3% | 0.00% | – |
Q2 2016 | $35,000 | – | 7,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Yu Fan | 112,044 | $532,000 | 6.17% |
Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |